We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell Solid on Geographic Expansion Amid Stiff Competition
Read MoreHide Full Article
On Feb 1, we issued an updated research report on Omnicell, Inc. (OMCL - Free Report) . The company has laid out its strategy of expanding into new markets. This strategy so far has been driving significant growth in the Non-Acute Care segment. However, a tough competitive landscape is a dampener. The stock carries a Zacks Rank #3 (Hold).
This developer and marketer of end-to-end automation solutions for the medication-use process has outperformed its industry over the past year. The stock has gained 46.3% against the industry’s 4.8% decline.
Outside the United States, healthcare providers are becoming increasingly aware of the benefits of automation. Additionally, there is substantial demand for adherence packaging equipment outside the domestic market. Given the fact that the international market is less than 1% penetrated with very few hospitals adopting medication control systems, Omnicell is rapidly expanding into new markets.
While the company continues to focus on the Middle East and South Africa, it sees greater adoption of technologies in other parts of the world, the latest area being Australia. Internationally, the company announced its first IV robotics deal and forayed into the South Korean market with several hospital locations.
We are also upbeat about the company successfully progressing through acquisitions and partnerships. Omnicell’s latest buyout is InPharmics, a Mississippi-based technology and services company which should help Omnicell expand the capabilities of its Performance Center. The company is witnessing solid cross-selling momentum within the total product platform and combined customer base, specifically for the company’s XR2, IV and Performance Center solutions in both the pipeline and the bookings.
Meanwhile, Omnicell faces intense competition in the medication management and supply chain solutions market. Stiff competition could result in pricing pressure and a reduced margin, which will affect the company’s performance in turn.
Also, company continues to battle escalating costs. Omnicell continues to expect higher costs in the upcoming quarters stemming from integration of new acquisitions and expenses related to the recently-launched XT series and IV workflow.
Key Picks
Some better-ranked stocks in the broader medical space are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
Varian Medical Systems’ long-term earnings growth rate is estimated at 8%. The stock flaunts a Zacks Rank #2 (Buy) at present.
CONMED’s long-term earnings growth rate is projected at 11.5%. The stock currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Omnicell Solid on Geographic Expansion Amid Stiff Competition
On Feb 1, we issued an updated research report on Omnicell, Inc. (OMCL - Free Report) . The company has laid out its strategy of expanding into new markets. This strategy so far has been driving significant growth in the Non-Acute Care segment. However, a tough competitive landscape is a dampener. The stock carries a Zacks Rank #3 (Hold).
This developer and marketer of end-to-end automation solutions for the medication-use process has outperformed its industry over the past year. The stock has gained 46.3% against the industry’s 4.8% decline.
Outside the United States, healthcare providers are becoming increasingly aware of the benefits of automation. Additionally, there is substantial demand for adherence packaging equipment outside the domestic market. Given the fact that the international market is less than 1% penetrated with very few hospitals adopting medication control systems, Omnicell is rapidly expanding into new markets.
While the company continues to focus on the Middle East and South Africa, it sees greater adoption of technologies in other parts of the world, the latest area being Australia. Internationally, the company announced its first IV robotics deal and forayed into the South Korean market with several hospital locations.
We are also upbeat about the company successfully progressing through acquisitions and partnerships. Omnicell’s latest buyout is InPharmics, a Mississippi-based technology and services company which should help Omnicell expand the capabilities of its Performance Center. The company is witnessing solid cross-selling momentum within the total product platform and combined customer base, specifically for the company’s XR2, IV and Performance Center solutions in both the pipeline and the bookings.
Meanwhile, Omnicell faces intense competition in the medication management and supply chain solutions market. Stiff competition could result in pricing pressure and a reduced margin, which will affect the company’s performance in turn.
Also, company continues to battle escalating costs. Omnicell continues to expect higher costs in the upcoming quarters stemming from integration of new acquisitions and expenses related to the recently-launched XT series and IV workflow.
Key Picks
Some better-ranked stocks in the broader medical space are Varian Medical Systems , AngioDynamics (ANGO - Free Report) and CONMED Corporation (CNMD - Free Report) .
AngioDynamics has a Zacks Rank of 1 (Strong Buy) and an expected revenue growth rate of 4.3% for fiscal 2019. You can see the complete list of today’s Zacks #1 Rank stocks here.
Varian Medical Systems’ long-term earnings growth rate is estimated at 8%. The stock flaunts a Zacks Rank #2 (Buy) at present.
CONMED’s long-term earnings growth rate is projected at 11.5%. The stock currently carries a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>